152 related articles for article (PubMed ID: 30106635)
1. Interpretation of Unexpectedly High Levels of Endocrine Tumor Markers.
Yu R
Endocr Pract; 2018 Sep; 24(9):841-847. PubMed ID: 30106635
[TBL] [Abstract][Full Text] [Related]
2. Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.
Conlon JM
Regul Pept; 2010 Nov; 165(1):5-11. PubMed ID: 19931574
[TBL] [Abstract][Full Text] [Related]
3. Practical markers used in the diagnosis of endocrine tumors.
Erickson LA; Lloyd RV
Adv Anat Pathol; 2004 Jul; 11(4):175-89. PubMed ID: 15220821
[TBL] [Abstract][Full Text] [Related]
4. ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus.
Giannetta E; Guarnotta V; Altieri B; Sciammarella C; Guadagno E; Malandrino P; Puliani G; Feola T; Isidori AM; Colao AAL; Faggiano A
Eur J Endocrinol; 2020 Dec; 183(6):R197-R215. PubMed ID: 33112280
[TBL] [Abstract][Full Text] [Related]
5. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract.
Schürmann G; Raeth U; Wiedenmann B; Buhr H; Herfarth C
World J Surg; 1992; 16(4):697-701; discussion 701-2. PubMed ID: 1413839
[TBL] [Abstract][Full Text] [Related]
6. Current concepts of tumor markers in bladder cancer.
Droller MJ
Urol Clin North Am; 2002 Feb; 29(1):229-34. PubMed ID: 12109349
[TBL] [Abstract][Full Text] [Related]
7. [Endocrine tumor].
Sasano H
Gan To Kagaku Ryoho; 2005 Jan; 32(1):121-4. PubMed ID: 15675597
[TBL] [Abstract][Full Text] [Related]
8. Medullary thyroid carcinomas express chromogranin A and a novel neuroendocrine protein recognized by monoclonal antibody HISL-19.
Deftos LJ; Woloszczuk W; Krisch I; Horvat G; Ulrich W; Neuhold N; Braun O; Reiner A; Srikanta S; Krisch K
Am J Med; 1988 Dec; 85(6):780-4. PubMed ID: 3195602
[TBL] [Abstract][Full Text] [Related]
9. The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors.
Rosa P; Gerdes HH
J Endocrinol Invest; 1994 Mar; 17(3):207-25. PubMed ID: 8051343
[No Abstract] [Full Text] [Related]
10. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
Ong SC; Schöder H; Patel SG; Tabangay-Lim IM; Doddamane I; Gönen M; Shaha AR; Tuttle RM; Shah JP; Larson SM
J Nucl Med; 2007 Apr; 48(4):501-7. PubMed ID: 17401085
[TBL] [Abstract][Full Text] [Related]
11. Incidentally discovered tumors of the endocrine glands.
Vardanian AJ; Hines OJ; Farrell JJ; Yeh MW
Future Oncol; 2007 Aug; 3(4):463-74. PubMed ID: 17661721
[TBL] [Abstract][Full Text] [Related]
12. Skin lesions in hereditary endocrine tumor syndromes.
Saggini A; Brandi ML
Endocr Pract; 2011; 17 Suppl 3():47-57. PubMed ID: 21613052
[TBL] [Abstract][Full Text] [Related]
13. Genetic predisposition to endocrine tumors: Diagnosis, surveillance and challenges in care.
Petr EJ; Else T
Semin Oncol; 2016 Oct; 43(5):582-590. PubMed ID: 27899191
[TBL] [Abstract][Full Text] [Related]
14. Fine needle aspiration cytology of endocrine neoplasms of the pancreas. Morphologic and immunocytochemical findings in 20 cases.
Jiménez-Heffernan JA; Vicandi B; López-Ferrer P; González-Peramato P; Pérez-Campos A; Viguer JM
Acta Cytol; 2004; 48(3):295-301. PubMed ID: 15192942
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A as tumor marker in medullary thyroid carcinoma.
Blind E; Schmidt-Gayk H; Sinn HP; O'Connor DT; Raue F
Thyroid; 1992; 2(1):5-10. PubMed ID: 1356053
[TBL] [Abstract][Full Text] [Related]
16. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
[TBL] [Abstract][Full Text] [Related]
17. Criteria and markers for malignancy in endocrine tumors.
de Krijger RR
Endocr Pathol; 2006; 17(2):107-8. PubMed ID: 17159242
[No Abstract] [Full Text] [Related]
18. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
20. [An immunohistochemical study and its clinical application for endocrine disorders using monoclonal antibodies].
Shimizu K; Eisenbarth GS; Shoji T
Nihon Ika Daigaku Zasshi; 1991 Dec; 58(6):615-20. PubMed ID: 1770115
[No Abstract] [Full Text] [Related]
[Next] [New Search]
